<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>                     <BR>                     <BR>                     INFORMATION FOR PATIENTS<BR>                     <BR>                        Before prescribing quinidine gluconate as prophylaxis against recurrence of atrial fibrillation, the physician should inform the patient of the risks and benefits to be expected (see <BR>                              CLINICAL PHARMACOLOGY<BR>                           ). Discussion should include the facts:<BR>                        <BR>                           that the goal of therapy will be a reduction (probably not to zero) in the frequency of episodes of atrial fibrillation; and<BR>                           that reduced frequency of fibrillatory episodes may be expected, if achieved, to bring symptomatic benefit; but<BR>                           that no data are available to show that reduced frequency of fibrillatory episodes will reduce the risks of irreversible harm through stroke or death; and in fact<BR>                           that such data as are available suggest that treatment with quinidine gluconate is likely to increase the patient's risk of death.<BR>                        <BR>                     <BR>                     <BR>                  <BR>               </P></DIV></HTML>